3-O-Methyldopa
| Names | |
|---|---|
| IUPAC name 2-Amino-3-(4-hydroxy-3-methoxyphenyl)propanoic acid. | |
| Other names 3-Methoxytyrosine; 3-Methoxydopa; L-3-O-Methyl-DOPA; 3-Methoxy-L-tyrosine; L-4-Hydroxy-3-methoxyphenylalanine; L-3-Methoxytyrosine; L-3-Methoxy-4-hydroxyphenylalanine | |
| Identifiers | |
| 3D model (JSmol) | |
| ChEBI | |
| ChemSpider | |
| PubChem CID | |
| UNII | |
| CompTox Dashboard (EPA) | |
| 
 | |
| 
 | |
| Properties | |
| C10H13NO4 | |
| Molar mass | 211.217 g·mol−1 | 
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references | |
3-O-Methyldopa (3-OMD) is one of the most important metabolites of L-DOPA, a drug used in the treatment of the Parkinson's disease.
3-O-methyldopa is produced by the methylation of L-DOPA by the enzyme catechol-O-methyltransferase. The necessary cofactor for this enzymatic reaction is s-adenosyl methionine (SAM). Its half-life (approximately 15 hours) is longer than L-DOPA's half-life, which is about one hour. This means that it is accumulated in the plasma and the brain of chronic L-DOPA therapy patients such as people suffering from Parkinson's disease.
3-OMD is often elevated in the plasma and cerebrospinal fluid of Parkinson's disease patients taking L-DOPA. It's serum levels are also elevated in patients with AADC deficit, making it a useful marker for screening of this disease.